Research programme: targeted inflammation and autoimmune therapeutics - Affibody/Swedish Orphan Biovitrum

Drug Profile

Research programme: targeted inflammation and autoimmune therapeutics - Affibody/Swedish Orphan Biovitrum

Alternative Names: IL-1 Affibody; SOBI 005; SOBI 006; Z-FC

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affibody; Biovitrum
  • Developer Affibody; Swedish Orphan Biovitrum
  • Class Proteins
  • Mechanism of Action Complement C5 inhibitors; Immunomodulators; Immunosuppressants; Interleukin 1 beta inhibitors; Interleukin 1 modulators; Th17 cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders
  • No development reported Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Sweden (Parenteral)
  • 22 Apr 2016 Swedish Orphan Biovitrum signs licensing agreement with Affibody for therapeutics targeting interleukin-1 for inflammatory diseases
  • 24 Nov 2015 Preclinical trials in Autoimmune disorders in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top